RT Journal Article
T1 Chronic Venous Disease during Pregnancy Causes a Systematic Increase in Maternal and Fetal Proinflammatory Markers
A1 Ortega, Miguel A.
A1 Gómez Lahoz, Ana M.
A1 Sanchez Trujillo, Lara
A1 Fraile Martínez, Oscar
A1 García Montero, Cielo
A1 Guijarro, Luis G.
A1 Bravo Arribas, Coral
A1 León Luis, Juan Antonio
A1 Saz, Jose V.
A1 Bujan, Julia
A1 García Honduvilla, Natalio
A1 Monserrat, Jorge
A1 Álvarez Mon, Melchor
AB Chronic venous disease (CVD) is a common vascular disorder characterized by increased venous hypertension and insufficient venous return from the lower limbs. Pregnancy is a high-risk situation for developing CVD. Approximately a third of the women will develop this condition during pregnancy, and similarly to arterial hypertensive disorders, previous evidence has described a plethora of alterations in placental structure and function in women with pregnancy-induced CVD. It is widely known that arterial-induced placenta dysfunction is accompanied by an important immune system alteration along with increased inflammatory markers, which may provide detrimental consequences for the women and their offspring. However, to our knowledge, there are still no data collected regarding cytokine profiling in women with pregnancy-induced CVD. Thus, the aim of the present work was to examine cytokine signatures in the serum of pregnant women (PW) with CVD and their newborns (NB). This study was conducted through a multiplex technique in 62 PW with pregnancy-induced CVD in comparison to 52 PW without CVD (HC) as well as their NB. Our results show significant alterations in a broad spectrum of inflammatory cytokines (IL-6, IL-12, TNF-α, IL-10, IL-13, IL-2, IL-7, IFN-γ, IL-4, IL-5, IL-21, IL-23, GM-CSF, chemokines (fractalkine), MIP-3α, and MIP-1β). Overall, we demonstrate that pregnancy-induced CVD is associated with a proinflammatory environment, therefore highlighting the potentially alarming consequences of this condition for maternal and fetal wellbeing.
PB MDPI
SN 1422-0067
YR 2022
FD 2022-08-11
LK https://hdl.handle.net/20.500.14352/72230
UL https://hdl.handle.net/20.500.14352/72230
LA eng
NO Unión Europea
NO Comunidad de Madrid
NO Instituto de Salud Carlos III
NO Halekulani S.L
DS Docta Complutense
RD 9 abr 2025